Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
dc.contributor.author | Pu, Robert T. | en_US |
dc.contributor.author | Yang, Jack | en_US |
dc.contributor.author | Wasserman, Patricia G. | en_US |
dc.contributor.author | Bhuiya, Tawfiqul | en_US |
dc.contributor.author | Griffith, Kent A. | en_US |
dc.contributor.author | Michael, Claire W. | en_US |
dc.date.accessioned | 2007-05-02T14:20:07Z | |
dc.date.available | 2007-05-02T14:20:07Z | |
dc.date.issued | 2006-05 | en_US |
dc.identifier.citation | Pu, Robert T.; Yang, Jack; Wasserman, Patricia G.; Bhuiya, Tawfiqul; Griffith, Kent A.; Michael, Claire W. (2006). "Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?." Diagnostic Cytopathology 34(5): 330-334. <http://hdl.handle.net/2027.42/50686> | en_US |
dc.identifier.issn | 8755-1039 | en_US |
dc.identifier.issn | 1097-0339 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/50686 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16604553&dopt=citation | en_US |
dc.description.abstract | Thyroid fine-needle aspiration (FNA) is a standard procedure for the clinical triage of thyroid nodules. The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate. The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change. Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial. A cohort of 303 thyroid FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision diagnosis compared to the FNA diagnosis in order to address this issue. Of this cohort, 87 cases had an FNA diagnosis of HLN while 216 cases had a diagnosis of FLN. Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma). The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision. There is no significant difference in predicting cancer between the two cytology diagnosis groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771). When sorting all the cases by the surgical diagnosis, while comparable for age at diagnosis, the cancer group having the higher proportion of male patients than the non-cancer group (28.7% versus 16.7%, P = 0.0259). Hurthle cell carcinoma patients are typically older than patients with other cancer diagnoses (59 versus 44, P = 0.0077). Our results suggest that an FNA diagnosis of HLN does not predict more malignancy than FLN. Males and older patients with a HLN FNA diagnosis carry a higher risk of Hurthle cell carcinoma upon thyroidectomy. Diagn. Cytopathol. 2006;34:330–334. © 2006 Wiley-Liss, Inc. | en_US |
dc.format.extent | 182952 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pathology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan ; Department of Pathology, University of Michigan Medical School, 1500 E. Medical Center Drive, Room 2G332/BOX 0054, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Biostatistic Unit, Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Long island Jewish Medical Center, New Hyde Park, New York | en_US |
dc.contributor.affiliationother | Long island Jewish Medical Center, New Hyde Park, New York | en_US |
dc.contributor.affiliationother | Long island Jewish Medical Center, New Hyde Park, New York | en_US |
dc.identifier.pmid | 16604553 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/50686/1/20440_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/dc.20440 | en_US |
dc.identifier.source | Diagnostic Cytopathology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.